Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

BACKGROUND: Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dementia. The recent advent of blood-based markers opens the door for more accessible...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichet Binette, Alexa, Palmqvist, Sebastian, Bali, Divya, Farrar, Gill, Buckley, Christopher J., Wolk, David A., Zetterberg, Henrik, Blennow, Kaj, Janelidze, Shorena, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966264/
https://www.ncbi.nlm.nih.gov/pubmed/35351181
http://dx.doi.org/10.1186/s13195-022-00990-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966264/
https://www.ncbi.nlm.nih.gov/pubmed/35351181
http://dx.doi.org/10.1186/s13195-022-00990-0

Ejemplares similares